Ranolazine

95635-55-5

C24H33N3O4

DMSO : 125 mg/mL (292.37 mM; Need ultrasonic)

Membrane Transporter/Ion Channel; Membrane Transporter/Ion Channel; Neuronal Signaling

Ranolazine is an antianginal medication. Target: Sodium Channel Ranolazine is believed to have its effects via altering the transcellular late sodium current. It affects the sodium-dependent calcium channels during myocardial ischemia in rabbits by altering the intracellular sodium level [1]. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia in rats [2]. The effects of ranolazine on the NaV 1.7 and NaV 1.8 sodium channels also make it potentially useful in the treatment of neuropathic pain. Ranolazine produced dose-dependant analgesia on mechanical allodynia induced by CFA injection, but had no effect on thermal hyperalgesia [3, 4].